192 related articles for article (PubMed ID: 25073227)
1. Denosumab-associated osteonecrosis of the jaw--a case report.
Vyas S; Hameed S; Murugaraj V
Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
[TBL] [Abstract][Full Text] [Related]
2. Denosumab-related osteonecrosis of the jaw.
Diz P; López-Cedrún JL; Arenaz J; Scully C
J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY
Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864
[TBL] [Abstract][Full Text] [Related]
4. Stage 0 osteonecrosis of the jaw in a patient on denosumab.
Aghaloo TL; Dry SM; Mallya S; Tetradis S
J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946
[TBL] [Abstract][Full Text] [Related]
5. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection.
Otto S; Baumann S; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2013 Oct; 41(7):694-8. PubMed ID: 23830772
[TBL] [Abstract][Full Text] [Related]
6. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
7. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
8. Denosumab osteonecrosis of the mandible: a new entity? A case report.
Pichardo SE; Kuypers SC; van Merkesteyn JP
J Craniomaxillofac Surg; 2013 Jun; 41(4):e65-9. PubMed ID: 23265807
[TBL] [Abstract][Full Text] [Related]
9. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
11. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
13. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
15. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
[TBL] [Abstract][Full Text] [Related]
16. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
Van den Wyngaert T; Wouters K; Huizing MT; Vermorken JB
Support Care Cancer; 2011 Dec; 19(12):2035-40. PubMed ID: 21203781
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
Taylor KH; Middlefell LS; Mizen KD
Br J Oral Maxillofac Surg; 2010 Apr; 48(3):221-3. PubMed ID: 19836866
[TBL] [Abstract][Full Text] [Related]
19. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J; Ettinger K; Naumann E; Beirne OR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):671-6. PubMed ID: 23159111
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]